Simple Office Spirometry
Simple Office Spirometry
Simple Office Spirometry
Introduction
In the past, primary care physicians assessed patients with asthma or COPD subjectively by
asking about symptom frequency and use of rescue inhalers, sometimes also considering the
presence of wheezing upon physical exam. Simple office spirometry provides an objective
measure of disease severity.
Spirometry measures how much air an individual can blow out and how fast. Primary care
practitioners will find simple office spirometry useful in the diagnosis and management of
obstructive and restrictive lung diseases, particularly to measure and monitor responses to
therapy for asthma and chronic obstructive pulmonary disease (COPD). Spirometry is also
useful in following the course and prognosis of many other lung diseases. Abnormal
spirometry results may indicate an increased risk of morbidity and mortality from asthma,
COPD, acute myocardial infarction, lung cancer, and stroke.
Until recently, inexpensive and user-friendly spirometers were not readily available for
office and clinic use. It’s now possible for primary care physicians and allied healthcare
professionals to obtain a spirometer and easily learn how to perform office spirometry and
apply the results for clinical decision making. Spirometry provides two numeric values that
are helpful in the assessment and monitoring of patients with compromised lung function:
the forced vital capacity (FVC) and forced expiratory volume measured over 1 second
(FEV1). Airways obstruction is characterized by a decrease in the FEV1/FVC ratio.
Forced Vital Capacity (FVC). The FVC is the total amount of air that can be exhaled
following as deep an inhalation as possible. A patient must try to exhale for at least
6 seconds to obtain a useful FVC measure. FVC was defined over 150 years ago by John
Hutchinson, an English surgeon who was the inventor of the spirometer. Hutchinson
found that when the FVC was large, a patient lived longer than when the FVC was small.
Lowered FVC values were often the result of tuberculosis, a common lung condition at
that time. Relatively low FVC is still a risk factor for premature death.
Several factors can influence the FVC value, the most important being height. Taller
people have larger thoracic cavities and thus larger FVC values. The average adult male has
a larger FVC than the average adult female. Disorders that limit the expansion of the chest
will reduce inflation of the lungs and therefore reduce the FVC. These include obesity,
kyphosis, scoliosis, rib fracture, compression of the spine, and pleural disease. Diaphragm
weakness can also reduce a person’s ability to take a deep breath.
Pneumonia is associated with a filling of the alveoli with fluid, reducing the amount of air
the lungs can hold, and therefore reducing the FVC. Congestive heart failure (CHF) also
increases lung fluid and reduces the FVC. Diseases that cause scarring of the lung tissue,
such as radiation-induced pulmonary fibrosis, make the lungs stiffer and more difficult to
fill, also reducing the FVC. Any disease associated with infiltrates (observed on a chest x-ray)
can reduce inflation and lower the FVC; thus, a low FVC is nonspecific.
Forced Expiratory Volume in 1 Second (FEV1). The FEV1 measures flow (and volume)
during the first second of an FVC maneuver and is often considered the most important
spirometry variable. FEV1 declines in direct and linear proportion with worsening of airways
obstruction, and FEV1 increases as obstruction is successfully treated. When expressed as a
percent of the predicted value, FEV1 is used to determine the degree of obstruction (mild,
moderate, or severe). The FEV1 should be used for serial comparisons when following
patients with asthma or COPD. Patients should be told their FEV1 percent (%) of predicted.
iii
Pet/Enright_v34 1/30/07 4:14 PM Page ii
The Ratio (FEV1/FVC). There is usually a very gradual transition between normal function
of the airways and mild airways obstruction. Physiologists have searched for a parameter that is
more sensitive than the FEV1 for detecting airways obstruction in its early stages, but none has
proven better than the index obtained by dividing the FEV1 by the vital capacity, as recommended
by Dr. Robert Tiffeneau in 1947. A ratio of less than 70% in adults (less than 80% in children)
indicates airways obstruction. Once a pattern of airways obstruction is established (usually due to
asthma or COPD), the ratio can be ignored during follow-up examinations.
Spirometry offers a method for objectively assessing the lung capacity, disease state, and severity
of patients with lung disease. In the past, subjective measures were the only office or clinic
resource available to the practitioner. Simple office spirometry allows doctors to rapidly obtain
results, to assess patient status during the office visit, and to provide meaningful recommendations
to patients based on these objective measures. The purpose of this booklet is to demonstrate
how these values can easily be applied to everyday clinical practice.
iv
Pet/Enright_v34 1/30/07 4:14 PM Page iii
Table
of Contents
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii
The Lungs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Airways Anatomy
Airways Pathology
Growth and Aging of the Lungs
Anthropometric Factors
Spirometry Indications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Post-Bronchodilator Spirometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
How to Interpret Spirometry Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
How to Recognize Normal and Abnormal Patterns
Normal Pattern (N)
Obstructive Pattern (Obs)
Restrictive Pattern (Reduced Inflation, No Obstruction [RINO])
Spirometry in the Diagnosis and Management of Lung Disease . . . . . . . . 13
Spirometry Results in Healthy Individuals
Chronic Dyspnea Workup
Diagnosing Asthma
Diagnosing Bronchial Hyper-Responsiveness (BHR)
Categorizing Asthma Severity
Detecting COPD in Adult Smokers
Chronic Bronchitis in Adult Smokers
Smoking and Spirometry
Detecting Restriction of Lung Volume
Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Glossary of Spirometry Terms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Bibliography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
The Lungs
➔ bronchi
➔
bronchioles
➔ ➔
➔
Airways Anatomy. The airways can be divided into the extrathoracic airways, including the
mouth, pharynx, vocal cords, and upper trachea (in the neck), and the intrathoracic airways,
including the lower trachea (within the chest), the carina, and the branching airways located
in the lungs.
Airways can also be classified as either large or small, with the small airways being less than 2 mm
in diameter. Traditional thinking has held that airways disease due to cigarette smoking begins
in the small airways. It is now known that the chronic airways inflammation associated with
smoking, as well as the eosinophilic inflammation associated with asthma, involves the entire
length of the airways and extends from the large upper airways (bronchi) to the small peripheral
airways (bronchioles).
COPD due to smoking develops over several decades in one out of five smokers. The disease is
characterized by a dissolution and destruction of the lung parenchyma resulting in a progressive
loss of lung elasticity and diminished airways support. The airways become “floppy” and may
collapse upon exhalation. Asthma-induced acute bronchospasm narrows airways by contracting
smooth muscle resulting in audible wheezing during exhalation. Finally, the upper airways may be
narrowed by vocal cord paralysis or dysfunction, or more rarely, by compression due to tumors.
Growth and Aging of the Lungs. Normal lung growth parallels the exponential increase in
height observed in children and teenagers, with lung function generally peaking during the 20s
or 30s. There is a slow decline in FVC and FEV1 extending throughout adulthood.
Lung growth may be slowed by smoking, cystic fibrosis, repeated pulmonary infections,
occupational exposures, or malnutrition. By the age of 25, patients with these risk factors may
have an FVC that is 20% to 30% lower than their peers. On the other hand, regular aerobic
exercise during the growth years may increase lung volume, so that by age 25, young athletes
may have obtained an FVC that is higher than their non-athletic counterparts. After about age
30, the FVC and FEV1 do not increase with exercise, although improvements in cardiovascular
fitness and endurance can be achieved.
After about age 30, lung tissue slowly begins to lose its elasticity, airways begin to close
prematurely during exhalation, and the FVC decreases by about 0.2 liters (L) per decade, even
in healthy individuals who have never smoked. Lung capacity starts out with a large reserve so
that, even by age 100, the FVC of a healthy person is usually not the limiting factor in the ability to
exercise. Many diseases, however, can cause the FVC to fall more quickly than 0.2 L per decade.
Normal Growth and Subsequent Decline in Lung Function in a Male of Average Height
4
FEV1 (L)
10 20 30 40 50 60 70 80
Age (years)
Anthropometric Factors. Age, height, and gender are each an independent factor affecting
lung function. Taller people have a larger frame size and thoracic cage, leading to larger lung
volumes and higher maximal flows, when compared to shorter people. For example, the predicted
(expected) mean FVC of a 40-year-old man who is tall (6' 4") is 6.0 L, while that of a short
40-year-old man (5' 4") is only 4.0 L. This means that the accurate measurement of
standing height (to the nearest half inch, without shoes) is very important when lung function
values are matched against predicted values.
Body weight is much less important than standing height when predicting most pulmonary
function (PF) values; thus, weight is not included in spirometry prediction equations.
Extremes in weight are associated with lower lung volumes: malnutrition causes reduced
diaphragm strength so that the patient cannot take as deep a breath as possible, and truncal
obesity restricts complete expansion of the chest cage. When total lung capacity is reduced, the
FEV1 is also proportionally reduced. An excellent index of the degree of obesity is the body
mass index (BMI) obtained by dividing the weight (in kilograms) by the height (in meters)
squared. Mildly reduced lung volumes in patients with a BMI above 30 may be entirely due
to their obesity. Changes in body weight result in changes in lung function. For example,
some of the improvement in FEV1 due to smoking cessation may be countered by the
associated weight gain.
Even when age, gender, and height are taken into consideration, the “normal” range of PF
variables for healthy individuals remains wide, often 80% to 120% of the predicted value.
This means that large changes with disease progression or therapy can easily occur while the
patient’s values remain within the normal range. Therefore, follow-up PF test results in adults
should be compared to their own baseline values.
Spirometry is the most useful test for detecting and managing asthma and COPD.
Spirometry is also indicated for use in several other clinical situations commonly
encountered by medical practitioners:
• Diagnosing asthma
• Categorizing asthma severity
• Identifying adult smokers who are developing COPD
• Staging the severity of COPD
• Chronic dyspnea workup
• Diagnosing restrictive lung disease
• Detecting bronchial hyper-responsiveness
• Measuring the effectiveness of bronchodilator or corticosteroid therapy
• Evaluating the pulmonary effects of workplace exposure to irritants
• Determining the risk of postoperative pulmonary complications
• Measuring the degree of impairment from respiratory disease
Pre-Test Preparations
Check Spirometer Accuracy. See the “Daily Spirometer Calibration Checks” section (p. 8) for details.
Measure Height Accurately. Predicted FVC and FEV1 values are greatly influenced by height.
Standing height should be measured to the nearest half inch (or centimeter) in stocking feet
prior to administering the first spirometry test. If the patient has obvious spinal deformities,
measure the arm span from fingertip to fingertip with arms outstretched against a wall. Arm
span should then be entered into the spirometer in place of standing height.
The technician or nurse is the critical factor in achieving good spirometry results since the
accuracy of the test depends on proper patient instruction. The patient should always be
coached to inhale maximally and then to BLAST out the air upon exhalation.
Explain the Procedure. Explain to the patient that the purpose of spirometry is to determine
how hard and fast air can be exhaled. It should be “like blowing out candles on a birthday
cake.” The patient should inhale as deeply as possible and, when the lungs are completely full,
quickly seal the lips around the mouthpiece and exhale as hard and fast as possible. Testing
should be done in the sitting position. If the patient sniffs air through the nose at the end of
the test, use noseclips.
Demonstrate the Maneuver. Demonstrate the FVC spirometry maneuver with a separate
mouthpiece or flow sensor. To emphasize that you are taking a very deep breath, throw back
your shoulders, widen your eyes, and stand on your toes. Next, stick out your tongue, place
the mouthpiece on top of your tongue, and seal your lips around it. Finally, dramatically BLAST
out as hard and as fast as possible for at least 6 seconds. Your vigorous demonstration will
prevent time and effort from being wasted on unacceptable maneuvers.
Coach the Patient. Ensure that the spirometer is ready to record the FVC maneuver. Coach
the patient to take as deep a breath as possible. Watch to ensure that the patient inhales deeply.
Encourage the patient to keep the chin up. Once he or she has sealed the lips around the
mouthpiece, shout loudly, “BLAST out the air!” Then tell the patient more quietly to, “Keep
going, keep going, blow out a little more air.” Some spirometers will help you by indicating
with a graph or tone that the patient is continuing to exhale air toward the end of the maneuver.
Step-by-Step Spirometry
Despite the use of accurate instruments, spirometry results may be misleading due to submaximal
breathing efforts. Unlike most other medical tests where the patient remains passive, accurate
spirometry results require athletic-like activity. The nurse or technician must coach the patient
to perform the breathing maneuvers in three phases: (1) instruct the patient to take as deep a
breath as possible; (2) loudly prompt the patient to BLAST out the air into the spirometer;
and (3) encourage continued exhalation for at least 6 seconds. Most problems with breathing
maneuvers can be detected by watching the patient’s body language during these three phases,
but resulting spirometry tracings can also show patterns of submaximal effort. Some spirometers
provide software that automatically checks each maneuver for acceptability and grades the
reproducibility of the FEV1 and FVC values.
If the patient does not inhale maximally, the FVC and FEV1 will be underestimated, and the
result may mimic a restrictive disorder. If the patient doesn’t blast out properly, the FEV1 may
be underestimated, and the result may mimic airways obstruction (false positive for COPD or
asthma). Even when the results from submaximal maneuvers do not lead to misdiagnoses, they
can be misleading when compared to results from previous or subsequent testing. For instance,
it may appear that the patient with COPD was helped by corticosteroid therapy, when the
apparent increase in FEV1 after therapy was actually due to submaximal inhalations during
pretreatment spirometry.
Results from two “Ground Zero” 9/11/01 World Trade Center responders
demonstrate the effect of improper maneuvers
The syringe will click against the stops with each stroke. Don’t “bang”
the plunger too forcefully.
Post-Bronchodilator Spirometry
If spirometry indicates airways obstruction, or if asthma is suspected, administration of a
bronchodilator (albuterol) followed by post-bronchodilator (BD) spirometry testing is often
clinically useful. Comparison of pre-BD and post-BD FEV1s helps determine if bronchodilator
therapy would be beneficial to the patient. If the patient has a long history of smoking, consider
using both albuterol and ipratropium (a long-acting anticholinergic bronchodilator) prior to
retesting. Following administration of the bronchodilator, wait 15 to 30 minutes and repeat
spirometry testing.
Modern office spirometers process numeric results automatically and print out a report that
includes data from each maneuver and a graph corresponding to those data points. Spirometer
interpretations are based on widely recognized clinical practice guidelines and assume an accurate
spirometer and good patient maneuver quality. Incorrect results or misleading interpretations
may result if these conditions are not met. The degree of bronchodilator response may also be
misinterpreted if either the baseline (pre-BD) or post-BD maneuver was of poor quality.
In order to determine the severity of lung function impairment, the FEV1 is expressed as a
percent of the predicted value. The predicted FEV1 for an average height 50-year-old man is
about 4.0 L, while that for an average 50-year-old woman is about 3.0 L. In general, patients
with severe COPD usually have an FEV1 of 0.5 to 1.0 L, while patients with moderate COPD
have an FEV1 of 1.0 to 1.5 L.
Some physiologic values, such as pH, are tightly controlled by the body and are not significantly
different in healthy men versus healthy women, tall versus short people, or children versus the
elderly. On the other hand, most spirometry variables vary widely, sometimes by as much as
20%, even in patients of the same age, height, and gender. Interpretation of initial numeric
spirometry results must take these factors into consideration. Spirometry reference equations
from the Third National Health and Nutrition Examination Study (NHANES III) are now
recommended for use throughout the United States. This study included thousands of healthy
men, women, and children, including African Americans and Hispanic Americans.
Normal Pattern (N). There are two ways to graph FVC maneuvers: the flow-volume (F-V) curve
and the traditional volume-time (V-T) graph. Both are shown on the following page and in the
examples which follow. The flow-volume curve was developed during the 1960s by Drs. Hyatt
and Fry and became popular due to the ease with which patterns of poor expiratory effort
and airways obstruction were quickly recognized. Note how flow quickly rises to a peak (in the
normal F-V graph) and then descends at a 45-degree angle until the FVC is reached at the
bottom right corner (like the sail on a boat).
The V-T graph was developed during the 1950s by Drs. Stead and Wells in Minneapolis.
The volume-time graph allows important measurement of the volume of air which was exhaled
1 second after the beginning of the maneuver (FEV1). Note how the curve then reaches a flat
plateau within 6 seconds, ending in the FVC.
Peak expiratory flow (PEF), as measured by mechanical meters used for home monitoring, can
be seen at the top of each F-V curve. The PEF measured by a spirometer is usually expressed in
liters per second, while the PEF measured by a mechanical meter is expressed in liters per
minute (10 L/s=600 LPM). Peak flow may be reduced in both obstructive and restrictive lung
diseases. PEF is less specific, less sensitive, and less accurate for detecting and following lung
diseases when compared to the FEV1 and FVC.
Obstructive Pattern (Obs). It’s easy to recognize the bowl-shaped pattern of airways obstruction
on the flow-volume curve. Flow quickly reaches a peak (within two tenths of a second, as in
healthy persons), but then it scoops or droops downward, so that subsequent flow is depressed,
and becomes very low as it reaches the FVC (4.0 L in this example). In severe airways obstruction
(usually due to COPD), the F-V curve is shaped like a rat’s tail. The difference between a normal
spirometry tracing and airways obstruction is more subtle on the volume-time graph. It takes more
time to exhale the air, so a flat plateau is often not obtained, even after 10 seconds.
Restrictive Pattern (Reduced Inflation, No Obstruction [RINO]). Patients with one of the many
conditions that restrict lung volumes have a low FVC. The shape of their flow-volume curve may
resemble the Transamerica building or the tip of a missile: after the sharp peak, the curve has a
steeper decline than normal, as the air is exhaled quickly. The FVC is only about 3.0 L in this
example. The volume-time curve shows that a flat plateau is rapidly obtained—often within
1 or 2 seconds—but the plateau is lower than normal.
Normal Pattern: N
% of
Predicted
FVC 4.2 L 127
FEV1 3.1 L 114
FEV1/FVC (%) 74%
Pattern: N
Comment: Despite his advanced age, Elmer performed a high-quality spirometry test. Note
the sharp peak on his flow-volume curve. His results show a normal FVC, normal FEV1, and
a normal ratio (N). Because of his normal results, post-bronchodilator testing was not performed.
Chronic Dyspnea Workup. Many lung diseases begin slowly and insidiously and finally manifest
themselves with the nonspecific symptom of dyspnea on exertion. Pulmonary function tests
(PFTs) are an essential component of the workup of such patients. In the outpatient clinic
setting, initial spirometry testing followed by further tests step-wise to refine the diagnosis is a
cost-effective method of carrying out PFTs. When a patient is hospitalized and a diagnosis is
needed within a day or two, a battery of PFTs may be ordered, often including spirometry
before and after the administration of a bronchodilator and the determination of absolute lung
volumes and diffusing capacity (DLCO). If the cause of dyspnea on exertion remains uncertain
following these tests, cardiopulmonary exercise testing should be considered.
Diagnosing Asthma. Spirometry testing before and after the administration of a bronchodilator
is indicated during the initial workup of patients suspected of having asthma and during most
follow-up office visits. Spirometry provides an objective measure of therapeutic response in the
management of asthma patients. Measuring the lung function of patients with asthma often
leads to the identification of a more severe asthma category. Thus, the measurement of lung
function with a spirometer can be more accurate than subjective assessment based on patient
reports of recent respiratory symptoms. Elderly persons with asthma are less likely than
younger patients to perceive the severity of their asthma.
Pre-BD
Post-BD
10 7
6
8
5
Flow (L/sec)
Volume (L)
6
4
4 3
2
2
1
1 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10
Volume (L) Time (sec)
Pre- % of Post- % of
BD* Predicted BD Predicted
FVC 2.9 L 57 4.7 L 92
FEV1 1.2 L 28 2.3 L 53
FEV1/FVC 41% 49%
Comment: Joyce’s history is consistent with COPD, asthma, gastroesophageal reflux disease
(GERD), or a combination thereof. Pre-BD spirometry results indicate severe airways
obstruction, as shown by the “drooping” or “scooping” pattern on the flow-volume curve,
which is verified by the low FEV1/FVC ratio (only 41%). This pre-BD pattern is consistent
with either COPD or asthma. However, the patient’s FEV1 nearly doubles on repeat
spirometry 15 minutes after administration of albuterol (post-BD). This large positive
response to a bronchodilator confirms asthma. Her post-BD FEV1 (53% of predicted) places
her in the severe, persistent asthma category.
Patients like Joyce will almost certainly respond very well to treatment with asthma controller
medications.
See the Appendix (p. 33) for a sample handout that may be given to patients with asthma
symptoms who have performed spirometry testing. Be sure to write in the FEV1 % of
predicted (in bold above) for the patient to take home.
*Each pre- and post-BD spirometry test session consists of at least three FVC maneuvers. However, for clarity in this and
the following examples, data and graphs show only the best maneuver from each test session.
Pre-BD
Post-BD
10 7
6
8
5
Flow (L/sec)
Volume (L)
6
4
4 3
2
2
1
1 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10
Volume (L) Time (sec)
Pre- % of Post- % of
BD Predicted BD Predicted
FVC 4.0 L 93 4.4 L 102
FEV1 2.5 L 71 3.0 L 86
FEV1/FVC 63% 68%
Comment: Despite a high peak flow (8.5 L/s=510 LPM), Amber’s pre-BD bowl-shaped
flow-volume curve is characteristic of airways obstruction as verified by her low FEV1/FVC
ratio (63%). Her FEV1 is 71% of predicted pre-BD, increasing to 86% of predicted following
albuterol (BD+). Her pre-bronchodilator spirometry test reveals that she has moderate, persistent
asthma. Daily inhaled corticosteroids are prescribed. At her 2-month follow-up visit, she reports
that she is now able to exercise without coughing or chest tightness and has not used her rescue
inhaler at all during the previous 4 weeks. Her follow-up spirometry values are within the
normal range, suggesting that the treatment suppressed airways inflammation and that she
has good asthma control.
Detecting COPD in Adult Smokers. Spirometry is the best means to detect the borderline-to-mild
airways obstruction of early COPD due to cigarette smoking. In these patients, the FEV1/FVC
ratio is below 70% even after administration of a bronchodilator. Once the diagnosis of COPD
is established, the course (or response to therapy) of mild-to-moderate COPD is best followed
by measuring changes in the FEV1. Continued smoking in a patient with airways obstruction
often results in an abnormally rapid decline in FEV1 over time (more than 0.5 L lost per
decade). Successful smoking cessation usually results in a small increase in FEV1 during the
first year, followed by a nearly normal rate of FEV1 decline thereafter.
8 6
Flow (L/sec)
5
Volume (L)
6
4
4 3
2
2
1
1 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10
Volume (L) Time (sec)
Pre- % of Post- % of
BD Predicted BD Predicted
FVC 2.7 L 63 3.3 L 77
FEV1 1.3 L 38 1.6 L 47
FEV1/FVC 48% 48%
Comment: Sarah’s spirometry shows a pattern of severe airways obstruction with an FEV1 of
only 38% of predicted. Her flow-volume curve has the shape and appearance of a rat’s tail.
On repeat spirometry, 30 minutes after administration of an albuterol inhaler and ipratropium,
her FEV1 increased only slightly (BD-). You diagnose COPD. Sarah admits to smoking since
age 17 and, faced with these results, would like to quit. You prescribe bupropion and refer her
to a smoking cessation program.
Chronic Bronchitis in Adult Smokers. Spirometry is also useful in the diagnosis and detection of
other lung ailments associated with smoking. Some smokers develop chronic lung infections
associated with a persistent cough that may be a sign of early COPD. Many smokers ignore
symptoms until they become severe. It is at this time that such patients present to your office.
6
8
5
Flow (L/sec)
Volume (L)
6
4
4 3
2
2
1
1 2 3 4 5 6 7 1 2 3 4 5 6 7 8 9 10
Volume (L) Time (sec)
Pre- % of Post- % of
BD Predicted BD Predicted
FVC 3.1 L 91 4.3 L 126
FEV1 2.9 L 97 2.9 L 97
FEV1/FVC 94% 67%
Smoking and Spirometry. The National Lung Health Education Program (NLHEP) recommends
that all cigarette smokers over age 45 should have spirometry performed by their primary care
physician. Incipient COPD can be detected in smokers in an obstructive pattern on spirometry
testing at least a decade before other signs or symptoms of COPD develop. Spirometry allows
the physician to confidently tell the smoker that he or she may develop COPD (emphysema)
and refer him or her to a local smoking cessation resource. These patients are more likely to
successfully quit smoking than are smoking patients who have not undergone spirometry testing.
If spirometry is normal, you should express relief that the smoker is not showing signs of
COPD but convey your concern that he or she remains at high risk of heart attack, stroke, and/or
lung cancer. Give the patient a handout like the one in the Appendix (p. 31) for adult smokers.
A patient’s functional lung age can be calculated by some spirometers and may serve as a prompt
for smokers to quit. Lung age is determined by calculating the age at which the patient’s measured
FEV1 would be considered normal. Smokers whose lung age is greater than their actual age
may then realize that smoking has caused their lungs to deteriorate and “age” faster than normal.
Calculating lung age is not appropriate for non-smokers and patients with asthma.
Detecting Restriction of Lung Volume. There are a number of disorders which lead to a restriction
of the lungs (reduction in lung volume). These restrictive disorders may be divided into three
groups: (1) intrinsic lung diseases which cause inflammation or scarring of the lung tissue
(interstitial lung diseases) or fill airspaces with exudate or debris (acute pneumonitis); (2)
extrinsic disorders of the chest wall which mechanically compress the lungs or limit their
expansion; and (3) neuromuscular disorders which decrease the ability of the respiratory
muscles to inflate and deflate the lungs. Spirometry is useful in detecting reduced lung volume
caused by restriction but rarely aids in the differentiation between the specific causes. Some
disorders, however, may be obvious from the history, physical examination, or chest x-ray.
Restriction leads to a decrease in all lung volumes—FVC, residual volume (RV), and total lung
capacity (TLC). Spirometry measures FVC, the volume of air that can be exhaled rapidly after
the patient takes as deep a breath as possible. At the end of a maximal exhalation, there is still
a residual volume of air left in the lungs. The TLC is the sum of the FVC and the RV. In the
absence of obstruction, a reduction in the FVC measured by spirometry is consistent with
reduced inflation, no obstruction of the lungs (RINO), often due to restriction.
When spirometry results reveal both a decreased FEV1/FVC ratio and reduced FVC, two
possibilities exist. The most common cause of this pattern is moderate-to-severe chronic airways
obstruction (an FEV1 less than about 1.5 L) causing an increase in the amount of air left in
the patient’s lungs at the end of maximal exhalation (hyperinflation and an increased residual
volume), necessarily associated with a low FVC. The second possibility is that a patient with
COPD or asthma also has a superimposed restrictive disorder. Ordering complete PFTs
(including TLC and DLCO) from a hospital-based pulmonary function laboratory and
comparing the most recent chest x-ray with previous ones can often resolve this question.
% of
Predicted
FVC 0.8 L 55
FEV1 0.7 L 51
FEV1/FVC 88%
Pattern: RINO
Comment: Frank’s flow-volume curve may look normal in shape, but it is very small for an
adult, and the numbers reveal a low FVC (55% of predicted) with a normal FEV1/FVC
ratio (88% of predicted). This is the pattern we call reduced inflation, no obstruction (RINO).
His chest x-ray showed questionable infiltrates. You order further PFTs, including a DLCO test
at the local hospital. His DLCO was only 40% of predicted, with a total lung capacity of 60%
of predicted, confirming restriction of his lung volumes. The pulmonologist interprets this
pattern as consistent with an interstitial lung disease.
% of
Predicted
FVC 3.6 L 80
FEV1 2.9 L 91
FEV1/FVC 81%
Pattern: N
Comment: Darlene has a borderline reduction in her FVC, and her FEV1 is normal. There are
no signs of airways obstruction, as shown by a normal FEV1/FVC ratio (approximately 70%
or greater is normal for adults). You worry about congestive heart failure (CHF) and order a
chest x-ray, which shows Kerley B lines and redirection of pulmonary blood flow toward the
upper lung fields. You order an echocardiogram, start her on diuretics, and recommend a low
sodium diet. Upon follow-up 1 month later, she has lost 8 pounds, reports better exercise tolerance,
and her FVC is now 95% of predicted. The echocardiogram shows an ejection fraction of 40%
with normal wall motion and no pericardial effusion. You are now certain that her borderline
low FVC was due to CHF and not obesity. During subsequent visits, you measure her FVC and
weight as objective measures of therapeutic control of her CHF.
Conclusion
Office spirometry provides a quick, easy, and inexpensive method of detecting airways obstruction
in adult cigarette smokers and patients of any age with respiratory symptoms. Spirometry also
provides an objective measurement of the severity of obstructive and restrictive lung diseases and
response to therapy. Airways obstruction is detected by a low FEV1/FVC ratio. Severity is
determined by the FEV1 % of predicted. A clinically important, positive response to therapy
is determined by an increase in the FEV1.
Authors:
Paul L. Enright, MD and Thomas L. Petty, MD
Acknowledgments: The authors thank E.P. Beeler for the spirometry graph examples,
Drs. A. Sonia Buist, Philip Quanjer, Gregory Wagner, Charles Irvin, and Dennis Doherty
for their reviews and helpful suggestions, and AlphaMedica, Inc., for the layout.
American Thoracic Society (ATS). The ATS is dedicated to providing advocacy and education
for patients with lung diseases. The ATS publishes guidelines for lung function testing,
including spirometry.
Body mass index (BMI). A common measure of obesity, BMI is calculated as the weight in
kilograms divided by the height in meters squared. A person with a BMI above 30 is usually
considered overweight, and this could result in a mildly low FVC.
Calibration syringe. A large 3.0 L cylinder with a rubber sealed piston used to check the
volume accuracy of spirometers.
Diffusing capacity (DLCO). A test done in a pulmonary function laboratory, which gives an
index of the ability of the lungs to rapidly take up oxygen. It is useful in the differential diagnosis
of airways obstruction and restriction of lung volumes.
Flow sensor. A sensor used to measure airflow. A flow sensor is also known as a
pneumotachometer. Some pneumotachometers are disposable (single-patient use), while
others are permanent and can be cleaned and repeatedly re-used.
Forced expiratory volume in 1 second (FEV1). The FEV1 is the most important spirometry
value. It measures the average flow rate during the first second of an FVC maneuver (expressed
in liters).
Forced expiratory volume in 6 seconds (FEV6). The volume of air rapidly exhaled within
6 seconds. The NHANES III reference equations allow the FEV6 to replace the traditional
FVC (see below for discussion of FVC). This makes spirometry easier for patients, since each
FVC maneuver needs to last only 6 seconds. The FEV6 is also known as the FVC6.
Forced vital capacity (FVC). FVC is the volume of air exhaled during the maneuver named
after it. The subject takes as deep a breath as possible and then quickly exhales (blasts) as much
air as possible.
Lower limit of the normal range (LLN). Spirometry results below the LLN are considered to
be abnormal. The LLN is based on reference values established by age, height, and gender in
matched healthy persons.
Metered-dose inhaler (MDI). A small, pressurized canister commonly used to deliver asthma
medications, such as albuterol, directly to the airways.
Methacholine challenge test. A test used to quickly rule out asthma in patients with symptoms
suggesting asthma but who have normal spirometry results.
NHANES III. The third National Health and Nutrition Examination Survey was conducted
by the National Center for Health Statistics at the Centers for Disease Control (CDC). It
collected information about the health and dietary habits of US residents.
NLHEP. The National Lung and Health Education Program promotes the use of spirometry
for the detection of COPD in adult smokers. They have published guidelines for the use of
office spirometry.
Predicted value of a spirometry parameter. Determined from the regression equation from
a large population study of healthy people such as NHANES III.
Pulmonary function tests (PFTs). Lung function tests performed using equipment such as
peak flow meters and/or spirometers. PFTs include spirometry, diffusing capacity (DLCO),
absolute lung volumes, such as total lung capacity (TLC) and residual volume (RV), and other
breathing tests.
RINO. Reduced inflation, no obstruction. The spirometry pattern of a low vital capacity
with a normal FEV1/FVC ratio. RINO is often, but not always, due to restriction.
Residual volume (RV). Amount of air remaining in the lungs at the end of a complete
exhalation. Spirometry cannot measure the RV, which is often elevated in patients with
COPD or asthma—a condition called hyperinflation.
Restriction. A reduction in all lung volumes (TLC, vital capacity, and residual volume).
Spacer. A device attached to MDI asthma inhalers, designed to improve deposition of the
drug deeper into the patient’s lungs.
Total lung capacity (TLC). Amount of air in the lungs when the patient inhales as deeply as
possible—also the air seen in the lungs when a chest x-ray is taken. The TLC is the sum of
the FVC and the residual volume (RV).
Two parameter spirometry. The most important two numbers from a spirometry test are the
FEV1/FVC ratio (categorized as N, Obs, or RINO) and the FEV1 % of predicted. A ratio
below 70% indicates obstruction in adults. The FEV1 % of predicted indicates the severity of
the abnormality and should be provided to the patient.
Bibliography
American Thoracic Society. Guidelines for the evaluation of impairment/disability in patients
with asthma. Am Rev Respir Dis. 1993;147:1056-1061.
American Thoracic Society. Lung function testing: selection of reference values and interpretive
strategies. Am Rev Respir Dis. 1991;144:1202-1218.
American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care
Med. 1995;152:1107-1136.
Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an
inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health
Study. JAMA. 1994;272:1497-1505.
Enright PL, Connett JE, Bailey WC. The FEV1/FEV6 predicts lung function decline in adult
smokers. Respir Med. 2002;96:444-449.
Enright PL, Lebowitz MD, Cockroft DW. Physiologic measures: pulmonary function tests.
Asthma outcome. Am J Respir Crit Care Med. 1994;149(2 pt 2):S9-S18.
Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment
in adults. A consensus statement from the National Lung Health Education Program. Chest.
2000;117:1146-1161.
Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT. Acute response
to bronchodilator: an imperfect guide for bronchodilator therapy in chronic airflow limitation.
Arch Intern Med. 1988;148:1949-1952.
Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the
general U.S. population [NHANES III]. Am J Respir Crit Care Med. 1999;159:179-187.
Hyatt RE, Scanlon PD, Nakamura M. Interpretation of Pulmonary Function Tests: A Practical
Guide. Philadelphia, Pa: Lippincott-Raven Publishers; 1997.
Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Ventilatory function and chronic mucus
hypersecretion as predictors of death from lung cancer. Am Rev Respir Dis. 1990;141:613-617.
Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function
in adults in the United States: data from the National Health and Nutrition Examination
Survey, 1988-1994. Arch Intern Med. 2000;160:1683-1689.
Morris JF, Temple W. Spirometric “lung age” estimation for motivating smoking cessation.
Prev Med. 1985;14:655-662.
NIH/National Heart, Lung, and Blood Institute. National Asthma Education and Prevention
Program (NAEPP) Clinical Practice Guidelines Expert Panel Report 2: Guidelines for the Diagnosis
and Management of Asthma. NIH Publication No. 97-4051. July 1997.
Nelson SB, Gardner RM, Crapo RO, Jensen RL. Performance evaluation of contemporary
spirometers. Chest. 1990;97:288-297.
Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis,
management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global
Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir
Crit Care Med. 2001;163:1256-1276.
Petty TL, Silvers GW, Stanford RE. The morphology and morphometry of small airways
disease (relevance to chronic obstructive pulmonary disease). Trans Am Clin Climatol Assoc.
1982;94:130-140.
Petty TL, Weinmann GG. Building a national strategy for the prevention and management of
and research in chronic obstructive pulmonary disease. National Heart, Lung, and Blood
Institute Workshop Summary; August 29-31, 1995; Bethesda, Md. JAMA. 1997;277:246-253.
Risser NL, Belcher DW. Adding spirometry, carbon monoxide, and pulmonary symptom
results to smoking cessation counseling: a randomized trial. J Gen Intern Med. 1990;5:16-22.
Social Security Administration. Disability Evaluation Under Social Security: A Handbook for
Physicians. HEW Publication No. SSA 05-10089. 1986.
Swanney MP, Jensen RL, Crichton DA, Beckert LE, Cardno LA, Crapo RO. FEV(6) is an
acceptable surrogate for FVC in the spirometric diagnosis of airways obstruction and restriction.
Am J Respir Crit Care Med. 2000;162(3 pt 1):917-919.
Tockman MS, Pearson JD, Fleg JL, et al. Rapid decline in FEV1. A new risk factor for
coronary disease mortality. Am J Respir Crit Care Med. 1995;151(2 pt 1):390-398.
❑ Your test result was within the normal range. You do not appear to be developing
COPD. However, as a smoker, you remain at high risk of developing a heart attack,
stroke, and/or lung cancer. Call the number at the bottom of this page for help with
smoking cessation.
❑ Your test result shows mild airways obstruction, suggesting that you are a “susceptible
smoker” who already shows signs of early COPD. You are unable to blow out air as
quickly as normal (your FEV1/FVC is low). If you continue smoking, you will eventually
develop disabling lung disease (in about 10-20 years). If you are able to successfully quit
smoking sometime soon, your lung function may return to normal levels and you will
probably never develop symptoms of COPD. Call the number at the bottom of this
page if you would like information about local resources to help you quit smoking.
❑ Your test result shows moderate-to-severe airways obstruction. You have COPD. If you
continue smoking, your lung disease will most likely get worse, and you will eventually
become short of breath while walking, climbing stairs, or doing other exercise. It is very
important that you seek help to stop smoking. If you are able to successfully quit smoking
sometime soon, you will probably regain a little lung function within 3 months, and
the abnormally rapid decline in your lung function which you have experienced due to
smoking will be stopped. Call the number at the bottom of this page for information
about local resources to help you quit smoking.
❑ Your test shows a low forced vital capacity (FVC). Your FVC is the total amount of air
that you exhaled, in liters (similar to quarts). Values below about 80% are abnormally
low and suggest that you are unable to inhale or exhale as much air as most healthy persons
of your age, height, gender, and race. Obesity may be one of the causes of a mildly
decreased FVC, and pneumonia is another. Consider asking your physician to review
this report at some time during the next couple of months.
____________________
Date
Pet/Enright_v34 1/30/07 4:15 PM Page 32
Pet/Enright_v34 1/30/07 4:15 PM Page 33
❑ Your test was within the normal range. If you recently had symptoms such as episodes
of shortness of breath with wheezing, chest tightness, or cough, you may have asthma,
but your lung function is normal today. Consider visiting a physician when you again
have asthma symptoms and then repeat this spirometry test. If you already know that
you have asthma, it is in good control.
❑ Your breathing test shows mild airways obstruction (some narrowing of your breathing
tubes). You are currently unable to blow out air quickly. This result may indicate asthma
that is not well controlled. Discuss with your physician medications to better control
your asthma.
❑ Your test shows a low forced vital capacity (FVC). Your FVC is the total amount of
air that you exhaled, in liters (similar to quarts). Values below about 80% are abnormally
low and suggest that you are unable to inhale or exhale as much air as most healthy
persons of your age, height, gender, and race. Obesity may be one of the causes of a
mildly decreased FVC, and pneumonia is another. Consider asking a physician to
review this report at some time during the next couple of months.
Your peak flow after inhaling a bronchodilator was ______ LPM (liters per minute). This
corresponds to______ L/s (divide LPM by 60). You can compare this value to the peak
flow that you measure using your own peak flow meter. The two numbers should match
within 1 L/s (60 LPM). If your asthma is currently in good control, today’s value may be
close to your best peak flow reading at home.
_______________________
Date
Pet/Enright_v34 1/30/07 4:15 PM Page 34
.ATIONAL ,UNG (EALTH %DUCATION
0ROGRAM .,(%0
. -AC!RTHUR "LVD 3UITE
)RVING 48
0HONE
&AX
7EB 3ITE NLHEPORG